Visit COVID-19 resources

[Skip to Content]

Intravitreal ranibizumab injection for the treatment of choroidal neovascularisation secondary to pathological myopia

28 November 2013

College Statement

The Royal College of Ophthalmologists welcomes the decision by The National Institute for Health and Care Excellence (NICE) to recommend Ranibizumab 0.5 mg intravitreal injection as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia. Prior to this decision there has been limited / variable access to anti-VEGF therapy for this group of patients.

The independent appraisal committee accepted the evidence that treatment reduced visual impairment in these patients and was both a clinically effective and cost effective treatment. The College believes that there should be no barrier to introduction of this therapy and expects clinical commissioning groups to support the rapid implementation of the guidance.